Triple-Negative Breast Cancer (TNBC)
Introduction
Triple-Negative Breast Cancer (TNBC) is a highly aggressive subtype of Breast Cancer characterized by the absence of three key receptors—estrogen (ER), progesterone (PR), and HER2. This makes it distinct from other breast cancers and more difficult to treat due to limited targeted therapies.
TNBC accounts for 10–20% of all breast cancer cases and disproportionately affects younger women, especially in developing countries like India.
Key Features of TNBC
1. Biological Characteristics
- Lacks hormone receptors (ER/PR) and HER2 protein
- Highly proliferative and aggressive
- Greater likelihood of metastasis, especially to lungs and brain
2. Clinical Challenges
- Limited treatment options (no hormone therapy or HER2-targeted drugs)
- High recurrence rate within 3–5 years
- Poorer prognosis compared to other breast cancer subtypes
Epidemiology and Indian Context
- India reports a rising burden of Breast Cancer, now the most common cancer among women
- TNBC prevalence is higher in Indian women (~25–30%) compared to Western populations (~10–15%)
- Contributing factors:
- Late diagnosis due to low awareness
- Genetic predisposition (e.g., BRCA mutations)
- Limited access to screening facilities
Risk Factors
- Genetic mutations (BRCA1)
- Younger age (<40 years)
- Obesity and sedentary lifestyle
- Reproductive factors (early menarche, late childbirth)
Diagnosis
- Mammography and ultrasound
- Biopsy with immunohistochemistry (to confirm absence of ER, PR, HER2)
Treatment Landscape
1. Conventional Approaches
- Chemotherapy remains the mainstay
- Surgery (lumpectomy/mastectomy)
- Radiation therapy
2. Emerging Therapies
- Immunotherapy (checkpoint inhibitors)
- PARP inhibitors for BRCA-mutated cases
- Targeted drug research ongoing globally
Recent Developments
- Advances in precision medicine and genomics are opening new treatment avenues
- Clinical trials exploring combination therapies
- Increased global focus under organizations like World Health Organization
Challenges in India
1. Healthcare Infrastructure
- Unequal access to cancer care between urban and rural areas
2. Financial Burden
- High out-of-pocket expenditure for chemotherapy and advanced therapies
3. Awareness Deficit
- Social stigma and lack of screening programs
4. Data Gaps
- Lack of comprehensive cancer registries for TNBC-specific data
Government Initiatives
- National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS)
- Ayushman Bharat for financial protection
- Population-based screening initiatives
Way Forward
1. Strengthening Early Detection
- Nationwide awareness campaigns
- Integration of screening at primary healthcare level
2. Research and Innovation
- Promote indigenous research on TNBC
- Encourage public-private partnerships in oncology
3. Affordable Treatment
- Expand insurance coverage
- Price regulation of cancer drugs
4. Capacity Building
- Train healthcare workers in early diagnosis and referral systems
Conclusion
Triple-Negative Breast Cancer represents a significant public health challenge due to its aggressive nature and limited treatment options. Addressing it requires a multi-pronged approach involving early detection, improved healthcare access, research innovation, and policy support. For India, tackling TNBC is crucial to reducing overall cancer mortality and achieving broader health goals.
Download Pdf
